Downloads
Abstract
Background: The study was designed to evaluate the response rate, time of treatment failure and adverse effects of second - generation TKIs (Afatinib) in a group of patients with advanced stage non - small cell lung cancer (NSCLC), carryinguncommon EGFR gene mutationsat Vietnam National Cancer Hospital.
Patients and methods: 25 patients were diagnosed with stage IIIC-IV non - small cell lung cancer (AJCC 8th), histopathology is adenocarcinoma, with uncommon EGFR gene mutations, treated with second - generation TKIs at Vietnam National Cancer Hospitalfrom January 2018 to March 2022
Results: The response rate reached 72% and the disease control rate was 92%. The median time of treatment free survival (mTTF) was 16.1 ± 4.3 months. 52% of patients had compounded mutation, 48% carried a single mutation. The three mutation kind with the highest prevalence were G719X (60%), S768I (44%), L861Q (16%). There were no significant differences in disease response, disease control and mTTF between the rare mutation subgroups. The double mutant had a significant mTTF of 19.1 months compared with the single mutant (7.3 months), p = 0.037.
Conclusion: First line of Afatinib treatment is effective in Vietnamese patients with advanced stage NSCLC with uncommon EGFR mutations. This choice of treatmenthad a good response and prolonged TTF with manageable toxicity. However, our results need to be further supported by further studies with larger sample sizes.
References
(IARC) G. Section of Cancer Information. 2018.
Bùi Diệu, Nguyễn Bá Đức, Trần Văn Thuấn Tình hình mắc ung thư tại Việt Nam 2004 - 2008 qua số liệu của 6 vùng. Tạp chí Ung thư học Việt Nam. 2010.
Prof James C-H Yang M, Lecia V Sequist, MD, Sarayut Lucien Geater, MD, Prof Chun-Ming Tsai, MD, Prof Tony Shu Kam Mok, MD, Prof Martin Schuler, MD et al. Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6. The Lancet Oncology. 2015;16:830-838.
Zhou C WY-L, Chen G, et al. OPTIMAL, Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open- label, randomised, phase 3 study. The Lancet Oncology. 2011;12:735-742.
Rosell R CE, Gervais R, et al Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012;13:239.
Mok TS WY, Thongprasert S, et al Gefitinib or carboplatin- paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361: 947.
Ramalingam SS, Vansteenkiste J, Planchard D, Cho BC, Gray JE, Ohe Y, et al. Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC. N Engl J Med. 2020;382:41-50.
James Chih-Hsin Yang M, PhD, Martin Schuler, MD, Sanjay Popat, FRCP, PhD, Keunchil Park, MD, Angela Märten, PhD, Edward S. Kim, MD. Afatinib for the Treatment of NSCLC Harboring Uncommon EGFR Mutations: A Database of 693 Cases. Journal of Thoracic Oncology. January 10, 2020;15:803-815.
Helena Čoupková RV. Afatinib in the Treatment of Advanced Non-Small Cell Lung Cancer with Rare EGFR (in exon 18-T179X) Mutation - a Case Report. 2018;31:380-383.
Jang Ho Cho M, 2; Sung Hee Lim, MD3; Ho Jung An, MD, PhD4; Ki Hwan Kim, MD5; Keon Uk Park, MD, PhD6; Eun Joo Kang, MD, PhD7; Yoon Hee Choi, MD8; Mi Sun Ahn, MD9; Myung Hee Lee, PhD10; Jong-Mu Sun, MD, PhD1; Se-Hoon Lee, MD, PhD1;Jin Seok Ahn, MD, PhD1; Keunchil Park, MD, PhD1; and Myung-Ju Ahn, MD, PhD. Osimertinib for Patients With Non–Small-CellLung Cancer Harboring Uncommon EGFRMutations: A Multicenter, Open-Label, Phase IITrial (KCSG-LU15-09). J Clin Oncol. 2019;1:488-495.
Nicolas Floc’h SL, Sue Bickerton, Afshan Ahmed, Jonathan Orme, Jelena Urosevic, Matthew J. Martin, Darren A.E. Cross, Byoung Chul Cho and Paul D. Smith. Osimertinib, an Irreversible Next-Generation EGFR Tyrosine Kinase Inhibitor, Exerts Antitumor Activity in Various Preclinical NSCLC Models Harboring the Uncommon EGFR Mutations G719X or L861Q or S768I. Molecular Cancer Therapeutics. November 2020;19:2298-307.
Jang Ho Cho M, 2; Sung Hee Lim, MD3; Ho Jung An, MD, PhD4; Ki Hwan Kim, MD5; Keon Uk Park, MD, PhD6; Eun Joo Kang, MD, PhD7;, Yoon Hee Choi MMSA, MD9; Myung Hee Lee, PhD10; Jong-Mu Sun, MD, PhD1; Se-Hoon Lee, MD, PhD1;, Jin Seok Ahn M, PhD1; Keunchil Park, MD, PhD1; and Myung-Ju Ahn, MD, PhD.
. J Clin Oncol. 2019:488-495.
Greulich H, Chen T-H, Feng W, Jänne PA, Alvarez JV, Zappaterra M, et al. Oncogenic transformation by inhibitor- sensitive and-resistant EGFR mutants. PLoS medicine. 2005;2:e313.
Hirsch FR V-GM, Bunn PA, et al. Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol. 2003;21:3798-3807.
Rosselle T Dungo 1 GMK. Afatinib: first global approval. Pubmed.gov. 2013 Sep;73:1503-15.
.
Ikemura S, Yasuda H, Matsumoto S, Kamada M, Hamamoto J, Masuzawa K, et al. Molecular dynamics simulation- guided drug sensitivity prediction for lung cancer with rare EGFR mutations. Proceedings of the National Academy of Sciences. 2019;116:10025-10030.
Yang JC SL, Geater SL, et al. : Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: Acombined post- hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6. Lancet Oncol. 2015:830-838.
Beau-Faller M, Prim N, Ruppert A-M, Nanni-Metéllus I, Lacave R, Lacroix L, et al. Rare EGFR exon 18 and exon 20 mutations in non-small-cell lung cancer on 10 117 patients: a multicentre observational study by the French ERMETIC- IFCT network. Annals of oncology. 2014;25:126-131.
Brückl W, Laack E, Hoffmann C, Zhou C, Wu Y-L. Afatinib in EGFR mutation-positive NSCLC harboring uncommon mutations: experience in ‘real-world’clinical practice.
Yang JC-H, Shih J-Y, Su W-C, Hsia T-C, Tsai C-M, Ou S-HI, et al. Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX- Lung 2): a phase 2 trial. 2012;13:539-548.
Kohsaka S, Nagano M, Ueno T, Suehara Y, Hayashi T, Shimada N, et al. A method of high-throughput functional evaluation of EGFR gene variants of unknown significance in cancer. Science translational medicine. 2017;9:eaan6566.
Janning M, Süptitz J, Albers-Leischner C, Delpy P, Tufman A, Velthaus-Rusik J-L, et al. Treatment outcome of atypical EGFR mutations in the German National Network Genomic Medicine Lung Cancer (nNGM). Annals of Oncology. 2022.
Halmos B, Tan EH, Soo RA, Cadranel J, Lee MK, Foucher P, et al. Impact of afatinib dose modification on safety and effectiveness in patients with EGFR mutation-positive advanced NSCLC: Results from a global real-world study (RealGiDo). Lung Cancer. 2019;127:103-111.
Wu YL ZC, Hu CP, Feng J, et al. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. Lancet Oncol 2014 Feb;15:213-222.
Yang J-H, Sequist L, Zhou C, Schuler M, Geater SL, Mok T, et al. Effect of dose adjustment on the safety and efficacy of afatinib for EGFR mutation-positive lung adenocarcinoma: post hoc analyses of the randomized LUX-Lung 3 and 6 trials. 2016;27:2103-2110.
| Published | 29-12-2024 | |
| Fulltext |
|
|
| Language |
|
|
| Issue | No. 80 (2022) | |
| Section | Original article | |
| DOI | 10.38103/jcmhch.80.12 | |
| Keywords | Ung thư phổi không tế bào nhỏ giai đoạn IV, đột biến EGFR hiếm, điều trị bằng TKIs thế hệ II Non - small cell lung cancer, advanced stage, uncommon EGFR mutation, second generation TKIs, Afatinib |
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright (c) 2022 Journal of Clinical Medicine Hue Central Hospital